Is Roflumilast-DALIRESP a hormonal drug or an anti-inflammatory drug?
Roflumilast Tablets (Roflumilast)-DALIRESP is not a hormonal drug, but a non-steroidal oral anti-inflammatory drug that is a phosphodiesterase 4 (PDE-4) inhibitor. Its mechanism of action is to inhibit the activity of PDE-4 enzyme, thereby reducing the inflammatory mediators released by inflammatory cells such as neutrophils and macrophages, thereby reducing airway inflammation and reducing lung tissue damage. Roflumilast is mainly used to treat patients with moderate to severe chronic obstructive pulmonary disease (COPD), especially those presenting with chronic bronchitis and frequent acute exacerbations. It is not a "hormone" in the traditional sense, nor is it a glucocorticoid drug, so it does not produce the common side effects associated with hormone drugs such as sodium and water retention, osteoporosis or elevated blood sugar.

Nonetheless, the anti-inflammatory effect of roflumilast is very significant. It can effectively reduce the number of COPD exacerbations per year and improve lung function (such as FEV₁) to a certain extent. Unlike inhaled hormones, roflumilast works in a systemic manner, so side effects such as loss of appetite, weight loss, gastrointestinal discomfort, headache, or mild depression may occur during use. However, these side effects usually gradually diminish after several weeks of continued use. Some doctors will recommend that patients start with a low dose (such as 250mcg) to enhance tolerance, and then transition to the standard 500mcg maintenance dose.
In short, although roflumilast has anti-inflammatory effects, its mechanism is different from that of hormonal drugs and it is not a steroid or glucocorticoid drug. It is a non-hormonal anti-inflammatory drug with a specific target and suitable for long-term use. It is of great significance in controlling the progression of COPD. Patients should closely follow the doctor's instructions during use to ensure efficacy and safety.
Reference materials:https://www.daliresp.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)